New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 6, 2013
16:16 EDTGHDXGenomic Health sees FY13 EPS ex-items 48c-68c, consensus 28c
Sees FY13 revenue $258M-$266M, consensus $262.4M. The company said, "In 2013, we plan to continue to invest in near-term opportunities to expand our global breast and colon cancer businesses in order to drive top-line revenue growth, and in our prostate cancer launch to build long-term value, and expect losses in the first and second quarters." Sees FY13 GAAP EPS (12c)-8c and non-GAAP basic EPS, excluding stock compensation expense, 48c-68c.
News For GHDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 28, 2015
05:21 EDTGHDXGenomic Health announces results from two studies for Oncotype DX
Genomic Health announced that, in addition to the positive five-year results from a group of patients with low Oncotype DX Recurrence Score results from the watershed ECOG-ACRIN Cancer Research Group's TAILORx study, sponsored by the National Cancer Institute, published in The New England Journal of Medicine, two additional positive international Oncotype DX clinical outcomes studies were presented at the 2015 European Cancer Congress. Together, these new studies establish Oncotype DX as the only genomic breast cancer test with prospective outcomes data in more than 5,700 patients to date, providing evidence that the biology information from the test should be included in treatment decisions. Reinforcing the published findings from TAILORx, two additional Oncotype DX clinical outcomes studies included positive results from a large, multi-center cohort from Clalit Health Services in Israel with follow-up exceeding 5 years, and a separate study of prospective survival results from the WSG Phase III Plan B trial in Germany.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use